Estonia - Esti - Ravimiamet

mylan pharmaceuticals limited - timolool+bimatoprost - silmatilgad, lahus - 5mg+0,3mg 1ml 3ml 1tk; 5mg+0,3mg 1ml 3ml 3tk

Estonia - Esti - Ravimiamet

mylan s.a.s. - dotsetakseel - infusioonilahuse kontsentraat ja lahusti - 40mg 1ml 2ml 1tk

Estonia - Esti - Ravimiamet

mylan s.a.s. - doksorubitsiin - infusioonilahuse kontsentraadi pulber - 2mg 1ml 10ml 1viaal; 2mg 1ml 50ml 1viaal

Estonia - Esti - Ravimiamet

mylan s.a.s. - epirubitsiin - süste-/infusioonilahus - 2mg 1ml 100ml 1tk

Estonia - Esti - Ravimiamet

mylan s.a.s. - oksaliplatiin - infusioonilahuse kontsentraat - 5mg 1ml 20ml 1tk; 5mg 1ml 10ml 1tk; 5mg 1ml 40ml 1tk

Uni Eropa - Esti - EMA (European Medicines Agency)

mylan dura gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antitrombootilised ained - clopidogrel on näidatud täiskasvanute ennetamise atherothrombotic sündmused:kannatavate patsientide müokardiinfarkti (paar päeva kuni vähem kui 35 päeva), ischaemic insult (7 päeva kuni vähem kui 6 kuud) või väljakujunenud perifeersete arterite haigus.

Uni Eropa - Esti - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Estonia - Esti - Ravimiamet

mylan s.a.s. - dobutamiin - infusioonilahuse kontsentraat - 250mg 20ml 20ml 10tk

Estonia - Esti - Ravimiamet

mylan s.p.a. - triasolaam - tablett - 0,125mg 20tk

Estonia - Esti - Ravimiamet

mylan hungary kft. - frovatriptaan - kaetud tablett - 2,5mg 2tk; 2,5mg 6tk